Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.

摘要: Abstract Objectives To review experience of secondary surgical cytoreduction (SSC) with hyperthermic intraperitoneal chemotherapy (IPHC). Methods Eligible patients ovarian cancer in whom pre-operative evaluation indicated that there was a good possibility disease could be resected to ≤5 mm underwent surgery followed by perfusion cisplatin (100 mg/m 2 ) or mitomycin C (30–40 mg total dose) heated 41–43°C (105.8–109.4°F) for 90 min. Data analysis were extracted from retrospective chart review. Results Eighteen and IPHC between 9/02 3/05. Characteristics median age 64 (37–77) years, mean prior laparotomies 1.4 (0–3), regimens 3.2 (0–7), time initial therapy 30.6 (1–88) months. Original histology: papillary serous 12, poorly differentiated adenocarcinoma 1, low malignant potential 2, mucinous 1 mixed subtypes 2. 13 had recurrent 5 persistent following front-line therapy. 15 received 3 C. The duration 9.8 (5–16) h. maximum dimension residual lesions at the end nil ( n =11), ≤2 mm =4), =2) ≤10 mm =1). Mean return bowel function 7 (5–20) days hospital discharge 11.5 (5–49) days. All developed CTEP grade metabolic hematologic toxicities. 4 toxicity occurred 72% 28%.There one peri-operative death due pulmonary embolus. Median progression-free interval 10 months overall survival 31 months. Improved outcome significantly related size postoperative chemotherapy. Conclusions is relatively well-tolerated procedure majority morbidity being associated surgery. When combined SSC it has extend quality life some warrants continued research. Randomized studies are needed earlier course disease.